Huntington's disease-like 1 (HDL1) is a rare autosomal dominant neurodegenerative disorder characterized by a clinical phenotype that closely resembles Huntington's disease but is caused by mutations in the prion protein gene (PRNP). HDL1 was first described in 2001 and represents an important differential diagnosis for patients presenting with choreiform movements and cognitive decline when genetic testing for Huntington's disease is negative[@young1999]. The disease is classified as a genetic prion disease, specifically a "HDR" (Huntington's disease-like) syndrome, with mutations in the prion protein gene leading to a phenotype that mimics the classic triad of Huntington's disease: motor impairment (chorea), cognitive decline, and psychiatric disturbances[@singeltop1999].
HDL1 is an extremely rare disorder, with only a limited number of families reported worldwide since its initial description. The disease appears to have equal sex distribution, consistent with autosomal dominant inheritance. Cases have been reported in various ethnic backgrounds, though the majority of documented cases come from European families. The prevalence is estimated to be less than 1 per million, making HDL1 one of the rarest neurodegenerative disorders. The disease typically presents in the third to sixth decade of life, similar to the typical age of onset in Huntington's disease[@nielsen2018].
¶ Genetics and Pathophysiology
HDL1 is caused by insertions of octapeptide repeat sequences in the PRNP gene located on chromosome 20p12. The prion protein (PrP) is a glycosylphosphatidylinositol-anchored protein highly expressed in the central nervous system, particularly in neurons. The wild-type prion protein contains five octapeptide repeats in the N-terminal domain (PHGGGWGQ motif). Pathogenic mutations in HDL1 involve the insertion of additional copies of this octapeptide repeat unit, typically ranging from 1 to 9 extra repeats[@young1999].
The number of inserted repeats correlates with disease severity and age of onset:
- 1-4 extra repeats: Later onset, milder phenotype
- 5-7 extra repeats: Typical HDL1 presentation
- 8+ extra repeats: Earlier onset, more severe progression
The cellular prion protein (PrP^C) is a 253-amino acid glycoprotein anchored to the cell membrane via a GPI anchor. It is expressed predominantly in the central and peripheral nervous system, with high expression in the hippocampus, cerebral cortex, basal ganglia, and cerebellum. The physiological function of PrP^C remains incompletely understood but appears to involve:
- Copper ion binding and homeostasis
- Synaptic function and plasticity
- Neuronal protection against oxidative stress
- Cell signaling through various receptors
- Metal ion transport and regulation
The pathological mechanism in HDL1 involves the conversion of the normal cellular prion protein (PrP^C) to an abnormal conformer (PrP^Sc), leading to neurotoxicity and neurodegeneration. This conformational change results in:
- Increased beta-sheet content in the protein structure
- Aggregation and formation of amyloid fibrils
- Resistance to proteolytic degradation
- Accumulation as extracellular plaques
- Neuronal loss and spongiform changes[@colby2011]
The prion protein mediates neurotoxicity through multiple mechanisms:
- Oxidative stress: Increased reactive oxygen species production
- Calcium dysregulation: Disruption of cellular calcium homeostasis
- Apoptosis: Activation of both intrinsic and extrinsic apoptotic pathways
- Synaptic dysfunction: Impaired neurotransmitter release and synaptic plasticity
- Autophagy impairment: Disruption of autophagic-lysosomal pathways[@hall2021]
Recent research has detailed several key pathways involved in prion protein-mediated neurotoxicity:
Endoplasmic Reticulum Stress: Mutant prion protein accumulates in the ER, triggering the unfolded protein response (UPR) and leading to neuronal apoptosis. The UPR activates three signaling branches: IRE1, PERK, and ATF6, all contributing to cell death pathways.
Mitochondrial Dysfunction: Prion protein mutations impair mitochondrial function through:
- Decreased mitochondrial membrane potential
- Reduced ATP production
- Increased mitochondrial permeability
-Release of cytochrome c and activation of apoptosis
Oxidative Stress: The prion protein normally participates in cellular antioxidant responses. Mutant forms lose this protective function, leading to:
- Increased lipid peroxidation
- Protein oxidation
- DNA damage
- Neuronal death[@cai2019]
Neuroinflammation: Activated microglia surround areas of prion protein deposition, releasing pro-inflammatory cytokines that contribute to neurodegeneration:
- Interleukin-1 beta (IL-1β)
- Tumor necrosis factor-alpha (TNF-α)
- Interleukin-6 (IL-6)
Patients with HDL1 present with features that are often indistinguishable from Huntington's disease, making differential diagnosis challenging.
The hallmark motor symptom of HDL1 is chorea—rapid, jerky, involuntary movements that typically begin in the face (facial grimacing), tongue (lingual dyskinesia), and distal extremities. The choreiform movements have several characteristics:
- Non-rhythmic, purposeless movements
- Semi-purposeful appearance (patients may incorporate movements into voluntary acts)
- Variable intensity, worsening with stress and improving with sleep
- Progressive involvement of axial and proximal muscles
- Gait abnormalities as the disease progresses[@nielsen2018]
In later disease stages, dystonia often emerges:
- Involuntary muscle contractions
- Abnormal postures (sustained twistings)
- Focal dystonia in cranial muscles
- Action dystonia during voluntary movement
As the disease progresses, parkinsonian features develop:
- Bradykinesia (slowed movements)
- Rigidity (increased muscle tone)
- Postural instability
- Tremor (less common than in Parkinson's)
- Shuffling gait
- Dysarthria: Slurred, variable speech due to facial chorea
- Dysphagia: Difficulty swallowing, risk of aspiration
- Gait instability: Falls due to combined chorea and dystonia
- Ocular motor abnormalities: Saccadic slowing
Cognitive decline follows a pattern similar to Huntington's disease, affecting multiple domains:
- Impaired planning and organization
- Reduced cognitive flexibility
- Difficulty with multitasking
- Poor judgment and decision-making
- Decreased verbal fluency
- Working memory impairment
- Difficulty with episodic recall
- Learning new information
- Spatial memory deficits
- Mental slowing (bradyphrenia)
- Reduced processing speed
- Decreased reaction time
- Attentional deficits
- Word-finding difficulties
- Reduced verbal output
- Impaired comprehension of complex information
- Echolalia in advanced stages
Psychiatric disturbances are common and may precede motor symptoms by years:
- Depressed mood
- Anhedonia (loss of pleasure)
- Sleep disturbances
- Appetite changes
- Fatigue
- Suicidal ideation
- Generalized anxiety
- Panic attacks
- Social anxiety
- Anxiety related to chorea awareness
- Visual hallucinations (less common)
- Auditory hallucinations
- Delusions (paranoid themes)
- Thought disorders
- Irritability
- Aggression
- Emotional lability
- Apathy
- Disinhibition
¶ Behavior and Social Impact
The combination of motor, cognitive, and psychiatric symptoms creates significant social impact:
- Social withdrawal due to chorea and psychiatric symptoms
- Unemployment due to functional impairment
- Relationship difficulties
- Financial strain from care needs
- Reduced quality of life
¶ Disease Course and Progression
The typical age of onset ranges from 30 to 60 years, with a mean of approximately 45 years. There is an inverse correlation between the number of octapeptide repeats and age of onset[@nielsen2018]:
- 5 extra repeats: onset around 50-55 years
- 7 extra repeats: onset around 40-45 years
- 9+ extra repeats: onset in the third decade
The disease progresses over 10-20 years through recognizably stages:
Early Stage (Years 1-5):
- Mild chorea, primarily facial and distal
- Minimal functional impairment
- Psychiatric symptoms (depression, anxiety)
- Subtle cognitive changes
- Preserved independence
Middle Stage (Years 5-12):
- Chorea becomes generalized
- Cognitive decline notable
- Psychiatric symptoms prominent
- Gait instability begins
- Requires some assistance
Late Stage (Years 12-20):
- Severe motor impairment
- Marked cognitive decline
- Severe dysphagia
- Wheelchair or bed bound
- Total care dependence
Common causes of mortality in HDL1:
- Aspiration pneumonia (due to dysphagia)
- Cachexia and malnutrition
- Infections (urinary tract, respiratory)
- Falls and trauma
- Suicide (especially in early stages)
The diagnostic workup involves:
- Assessment of chorea severity (quantified using standardized scales)
- Evaluation of cognitive function (MMSE, MoCA)
- Psychiatric assessment
- Assessment of functional abilities
- Negative HTT gene testing (CAG repeat < 36)
- PRNP gene sequencing identifying octapeptide repeat insertions
- Analysis of repeat number for prognostic information
MRI Brain:
- Caudate nucleus atrophy
- Putamen atrophy
- Cortical atrophy (particularly frontal)
- Ventricular enlargement
- White matter changes
FDG-PET:
- Hypometabolism in striatum
- Hypometabolism in frontal cortex
- Pattern similar to Huntington's disease
Diffusion Tensor Imaging (DTI):
- Reduced fractional anisotropy in striatum
- White matter tract involvement
- Cerebrospinal fluid (CSF): Typically normal; 14-3-3 protein may be elevated
- EEG: May show slowing in advanced stages
Distinguishing HDL1 from other conditions is critical:
- Normal PRNP sequencing
- Expanded CAG repeat in HTT
- JPH3 gene mutation
- Similar phenotype to HDL1
- More common in African populations
- Earlier onset
- Non-progressive
- No cognitive decline
- Ataxia rather than chorea
- Eye movement abnormalities
- Specific genetic mutations
- Acanthocytes on blood smear
- Elevated creatine kinase
- Specific genetic mutations (VPS13A)
- History of dopamine-blocking drugs
- Resolution after drug cessation
- No genetic mutation
- Neurofilament light chain (NfL): Elevated in CSF and blood
- Tau protein: May be elevated
- 14-3-3 protein: Present in CSF
- Total tau: Marker of neuronal injury
- Striatal glucose hypometabolism
- Caudate/putamen atrophy on MRI
- White matter integrity loss on DTI
There is currently no disease-modifying treatment for HDL1. Management is symptomatic and supportive.
For Chorea:
- Tetrabenazine: Dopamine-depleting agent; reduces chorea (dose 12.5-100 mg/day in divided doses)
- Deutetrabenazine: Deuterated tetrabenazine; better side effect profile
- Valbenazine: Once-daily dosing; FDA-approved for Huntington's chorea
- Antipsychotics: Haloperidol, olanzapine, risperidone (caution for side effects)
For Psychiatric Symptoms:
- Depression: SSRIs (fluoxetine, sertraline, citalopram), SNRIs (venlafaxine)
- Anxiety: Buspirone, benzodiazepines (short-term use)
- Psychosis: Atypical antipsychotics (quetiapine, clozapine)
- Irritability: Mood stabilizers (valproate, lamotrigine)
For Cognitive Symptoms:
- No effective pharmacological treatments
- Avoid anticholinergic medications
- Monitor for drug-induced cognitive impairment
Physical Therapy:
- Maintain mobility
- Prevent contractures
- Fall prevention strategies
- Exercise programs
Occupational Therapy:
- Home safety assessments
- Assistive device recommendations
- Functional adaptation
Speech Therapy:
- Dysarthria management
- Swallowing assessment and strategies
- Communication aids
Nutritional Support:
- Dietary modification for dysphagia
- Weight monitoring
- Vitamin supplementation
Psychological Support:
- Patient and family counseling
- Support groups
- Cognitive behavioral therapy
Prion Protein-Targeting Approaches:
Prion Protein Knockdown:
- Antisense oligonucleotides (ASOs)
- RNA interference (RNAi)
- Small interfering RNAs (siRNAs)
Antibody-Based Therapies:
- Anti-PrP monoclonal antibodies
- Passive immunization approaches
Small Molecule Inhibitors:
- Compounds targeting PrP^Sc formation
- Aggregation inhibitors
Immunomodulation:
- Approaches to enhance clearance
Chorea Management:
- Novel VMAT2 inhibitors
- Glycine transport inhibitors
Neuroprotection:
- Antioxidant therapies
- Mitochondrial protectants
- Anti-apoptotic agents
Cognitive Enhancement:
- symptomatic cognitive enhancers (limited efficacy)[@masullo2019]
Several animal models have been developed to study HDL1:
- PrP-84dup: Mouse model with 84-base pair octapeptide repeat insertion
- PrP-96dup: Model with 96-base pair insertion
- PrP-Octapeptide Insertion Lines: Multiple lines with varying repeat sizes
- Ataxia
- Motor dysfunction
- Cognitive deficits
- Prion protein deposition
- Spongiform changes
Animal models have been used to test:
- Prion protein-lowering approaches
- Aggregation inhibitors
- Neuroprotective agents
- Immunotherapies[@sanders2016]
-
Understanding Pathogenesis
- Mechanisms of prion protein-mediated neurotoxicity
- Role of specific protein domains
- Interaction with cellular partners
-
Biomarker Development
- Early detection markers
- Disease progression markers
- Treatment response markers
-
Therapeutic Development
- Prion protein-targeting drugs
- Gene therapy approaches
- Cell-based therapies
-
Natural History
- Disease progression patterns
- Genotype-phenotype correlations
- Biomarker correlations
No clinical trials specifically for HDL1 have been completed. However, therapies developed for other prion diseases (including Creutzfeldt-Jakob disease) may be applicable:
- Antisense oligonucleotide therapies
- Antibody therapies
- Small molecule inhibitors
HDL1 is part of the spectrum of human prion diseases:
- Gerstmann-Sträussler-Scheinker syndrome (GSS): Typically ataxic presentation
- Fatal familial insomnia (FFI): Sleep disruption as primary symptom
- Creutzfeldt-Jakob disease (CJD): Rapidly progressive dementia
- Variably protease-sensitive prionopathy (VPSPr): Novel phenotype
- Sporadic CJD: Most common prion disease
- Sporadic fatal insomnia
- Variant CJD: BSE-associated
- Iatrogenic CJD: Infection-related
Prion protein dysfunction is increasingly recognized in other conditions:
Alzheimer's Disease:
- PrP interacts with amyloid-beta
- May modulate toxicity
- Potential therapeutic implications
Parkinson's Disease:
- PrP in dopaminergic neurons
- Alpha-synuclein interactions
Huntington's Disease:
- Similar clinical phenotype
- Overlapping pathogenic mechanisms
Postmortem examination reveals:
- Cortical atrophy (particularly frontal)
- Striatal atrophy (caudate and putamen)
- Ventricular enlargement
- Thalamic involvement
Spongiform Changes:
- Vacuolation throughout gray matter
- Most prominent in cerebral cortex
- Basal ganglia involvement
- Cerebellar changes
Prion Protein Deposition:
- Extracellular amyloid plaques (in some cases)
- Synaptic PrP deposition
- Perivacuolar pattern
- Astrocytic gliosis around deposits
Neuronal Loss:
- Cortical neurons
- Striatal neurons
- Cerebellar neurons
- Specific vulnerable populations
Gliosis:
- Astrocytosis (GFAP positive)
- Microglial activation
- Present throughout affected regions
Additional Findings:
- Neurofibrillary tangles (variable)
- Amyloid angiopathy (some cases)
¶ Prognosis and Quality of Life
Negative Prognostic Factors:
- Early age of onset
- Large number of repeats
- Rapid progression of symptoms
- Early cognitive impairment
- Early psychiatric symptoms
Positive Prognostic Factors:
- Later age of onset
- Smaller repeat insertions
- Slower progression
- Good response to symptomatic treatment
Managing quality of life involves:
- Early diagnosis and counseling
- Symptomatic treatment optimization
- Supportive care services
- Caregiver support
- Advance care planning
- Palliative care integration
Huntington's disease-like 1 (HDL1) represents an important differential diagnosis for patients with Huntington's disease phenotype. Caused by octapeptide repeat insertions in the PRNP gene, this rare disorder shares clinical features with Huntington's disease while having distinct pathogenic mechanisms related to prion protein misfolding. Although no disease-modifying treatments exist, ongoing research into prion protein biology and therapeutic approaches offers hope for future interventions. Accurate diagnosis is critical for genetic counseling, prognostic planning, and potential enrollment in clinical trials as new therapies emerge. The relationship between HDL1 and other prion diseases, as well as the broader spectrum of neurodegenerative disorders, continues to provide insights into disease mechanisms and potential therapeutic targets[@puoti2020].
- Young K, et al, Octapeptide repeat insertions in the prion protein gene (1999)
- Colby DW, Prusiner SB, Prions (2011)
- Nielsen D, et al, Clinical characteristics of Hungarian patients with HDL1 (2018)
- Puoti G, et al, Human prion diseases: molecular basis and therapeutic approaches (2020)
- Singeltop SF, et al, HDL1: a third locus? Neurology (1999)
- Kovacs GG, et al, Neuropathology of Human Prion Diseases (2021)
- Zerr I, et al, Clinical diagnosis of human prion diseases (2020)
- Geschwind MD, Prion Diseases (2021)
- Auluck PK, et al, Mechanisms of Prion Protein-mediated Neurotoxicity (2002)
- Cao C, et al, Prion protein aggregation and neurotoxicity in prion diseases (2018)
- Hernandez JC, et al, Genetic Prion Diseases: Update on PRNP Mutations and Neurodegeneration (2020)
- Wiener A, et al, Prion Protein Mutants with Octapeptide Repeats: Molecular Mechanisms (2019)
- Sanders A, et al, Cybrid models of prion disease with mutant PRNP (2016)
- Westergard L, et al, Prion protein misfolding and neurotoxicity in cell culture (2021)
- Hall AM, et al, Neurodegeneration in Prion Disease: Role of Autophagy (2021)
- Jiang Y, et al, Prion protein-mediated cell signaling in neurodegeneration (2019)
- Forlonel G, et al, Neuroprotective strategies in prion diseases (2014)
- Masullo M, et al, Therapeutic approaches to prion diseases (2019)
- Cai S, et al, Prion protein, copper, and oxidative stress in neurodegeneration (2019)